Naproxcinod is an investigational drug.
There have been 9 clinical trials for Naproxcinod.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2007.
The most common disease conditions in clinical trials are Osteoarthritis, Hypertension, and Osteoarthritis, Knee. The leading clinical trial sponsors are NicOx and [disabled in preview].